Somatostatin modulates insulin-degrading-enzyme metabolism: Implications for the regulation of microglia activity in AD

PLoS ONE

Volumn 7, Issue 4, 2012, Pages

  Tundo, Grazia ^a   Ciaccio, Chiara ^a   Sbardella, Diego ^a,b   Boraso, Mariaserena ^c   Viviani, Barbara ^c   Coletta, Massimiliano ^a,b   Marini, Stefano ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b Interuniversity Consortium for the Research on the Chemistry of Metals in Biological Systems   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; INSULINASE; OCTREOTIDE; SOMATOSTATIN; AMYLOID BETA PROTEIN[1-40]; GELATINASE B; PEPTIDE FRAGMENT;

ALZHEIMER DISEASE; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME METABOLISM; ENZYME REGULATION; ENZYME RELEASE; GENE SILENCING; MICROGLIA; MOUSE; NEWBORN; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; RAT; ANIMAL; CELL LINE; CHEMISTRY; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PROTEIN MULTIMERIZATION; PROTEIN SECONDARY STRUCTURE; SECRETION; SPRAGUE DAWLEY RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; CELL LINE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; INSULYSIN; MATRIX METALLOPROTEINASE 9; MICE; MICROGLIA; OCTREOTIDE; PEPTIDE FRAGMENTS; PROTEIN MULTIMERIZATION; PROTEIN STRUCTURE, SECONDARY; PROTEOLYSIS; RATS; RATS, SPRAGUE-DAWLEY; SOMATOSTATIN;

EID: 84859241651     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0034376     Document Type: Article

References (43)

1. Crouch PJ, Harding SM, White AR, Camakaris J, Bush AI, et al. (2008) Mechanism of Abeta mediated neurodegeneration in Alzheimer's Disease. Int J Biochem Cell Biol 40: 181-198.
2. Evin G, Weidemann A, (2002) Biogenesis and metabolism of Alzheimer's disease Aß amyloid peptides. Peptides 23: 1285-1297.
3. Miners JS, Baig S, Palmer LE, Kehoe PG, Love S, (2008) Aß-degrading enzymes in Alzheimer's disease. Brain Pathology 18: 240-252.
4. Backstrom JR, Lim GP, Cullen MJ, Tökés ZA, (1996) Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40). J Neurosci 15: 7910-7919.
5. Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, (1998) Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 273: 32730-32738.
6. Iwata N, Tsubuki S, Takaki T, (2001) Metabolic regulation of brain A. by neprilysin. Science 292: 1550-1552.
7. Wang DS, Dickson DW, Malter JS, (2006) ß-amyloid degradation and Alzheimer's disease. J Biomed Biotechnol 3: 1-12.
8. Duckworth WC, Bennett RG, Hamel FG, (1998) Insulin degradation: progress and potential. Endocr Rev 19: 608-624.
9. Cook DG, Leverenz JB, McMillan PJ, Kulstad JJ, Ericksen S, et al. (2003) Reduced hippocampal insulin-degrading zenzyme in late-onset Alzheimer's disease is associated with the apolipoprotein E-epsilon4 allele. Am J Pathol 162: 313-319.
10. Bernstein HG, Ansorge S, Riederer P, Reiser M, Frölich L, et al. (1999) Insulin degrading enzyme in the Alzheimer's disease brain: prominent localization in neurons and senile plaques. Neuroscience Letters 263: 161-164.
11. Affholter JA, Hsieh CL, Francke U, Roth RA, (1990) Insulin-degrading enzyme: stable expression of the human complementary DNA, characterization of its protein product, and chromosomal mapping of the human and mouse genes. Mol Endocrinol 8: 1125-1135.
12. Espinosa R, Lemons RS, Perlman RK, Kuo WL, Rosner MR, et al. (1991) Localization of the gene encoding insulin-degrading-enzyme to human chromosome10, bands q23q25. Cytog Cell Gen 57: 184-186.
13. Farris W, Mansourian S, Leissring MA, Eckman EA, Bertram L, et al. (2004) Partial loss-of-function mutations in insulin-degrading enzyme that induce diabetes also impair degradation of amyloid beta-protein. Am J Pathol 164: 1425-1434.
14. Ertekin-Taner N, Allen M, Fadale D, Scanlin L, Younkin L, et al. (2004) Genetic variants in a haplotype block spanning IDE are significantly associated with plasma Abeta42 levels and risk for Alzhimer disease. Hum Mutat 23: 334-342.
15. Feuk L, McCarthy S, Andersson B, Prince JA, Brookes AJ, (2005) Mutation screening of a haplotypes block around the insulin degrading enzyme gene and association with Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet 136: 69-71.
16. Björk BF, Katzov H, Kehoe P, Fratiglioni L, Winblad B, et al. (2007) Positive association between risk for late-onset Alzheimer disease and genetic variation in IDE. Neurobiol Aging 28: 1374-1380.
17. Ciaccio C, Tundo GR, Grasso G, Spoto G, Marasco D, et al. (2009) Somatostatin: a novel substrate and a modulator of insulin-degrading enzyme activity. J Mol Biol 385: 1556-1567.
18. Davis KL, Mohs RC, Marin DB, Purohit DP, Perl DP, et al. (1999) Neuropeptide abnormalities in patients with early Alzheimer disease. Arch Gen Psych 56: 981-987.
19. Nilsson CL, Brinkmalm A, Minthon L, Blennow K, Ekman R, (2001) Processing of neuropeptide Y, galanin, and somatostatin in the cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia. Peptides 22: 2105-2112.
20. Cervia D, Bagnoli P, (2007) An update on somatostatin receptor signaling in native systems and new insights on their pathophysiology. Pharmacol Ther 116: 322-341.
21. Van Uden E, Veinbergs I, Mallory M, Orlando R, Masliah E, (1999) A novel role for receptor associated protein in somatostatin modulation: implications for Alzheimer's disease. Neuroscience 88: 687-700.
22. Saito T, Iwata N, Tsubuki S, Takaki T, Takano J, (2005) Somatostatin regulates brain amyloid peptide A.42 through modulation of proteolytic degradation. Nat Medicine 11: 434-439.
23. Craft S, Asthana S, Newcomer JW, Wilkinson CW, Matos IT, et al. (1999) Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch Gen Psych 56: 1135-1140.
24. Watson GS, Baker LD, Cholerton BA, Rhoads KW, Merriam GR, et al. (2009) Effects of insulin and octreotide on memory and growth hormone in Alzheimer's disease. J Alzheimers Dis 18: 595-602.
25. Doggrell SA, (2004) The potential of activation of somatostatinergic neurotransmission with FK960 in Alzheimer's disease. Expert Opin Investig Drugs 13: 69-72.
26. Tokita K, Inoue T, Yamazaki S, Wang F, Yamaji T, et al. (2005) FK962, a novel enhancer of somatostatin release, exerts cognitive-enhancing actions in rats. Eur J Pharmacol 527: 111-120.
27. Doraiswamy PM, Xiong GL, (2006) Pharmacological strategies for the prevention of Alzheimer's disease. Expert Opin Pharmacother 7: 1-10.
28. Leissring MA, Farris W, Chang AY, Walsh DM, Wu X, et al. (2003) Enhanced proteolysis of beta-amyloid in APP transgenic mice prevents plaque formation,secondary pathology, and premature death. Neuron 40: 1087-1093.
29. Yan P, Hu X, Song H, Yin K, Bateman RJ, (2006) Matrix metalloproteinase-9 degrades amyloid-beta fibrils in vitro and compact plaques in situ. J Biol Chem 281: 24566-24574.
30. Feindt J, Schmidt A, Mentlein R, (1998) Receptors and effects of the inhibitory neuropeptide somatostatin in microglial cells. Brain Res Mol Brain Res 60: 228-233.
31. Fleisher-Berkovich S, Filipovich-Rimon T, Ben-Shmuel S, Hülsmann C, Kummer MP, et al. (2010) Distinct modulation of microglial amyloid β phagocytosis and migration by neuropeptides. J Neuroinflammation 7: 61.
32. Bitting L, Naidu A, Cordell B, Murphy GM, (1996) Beta-amyloid peptide secretion by a microglial cell line is induced by beta-amyloid-(25-35) and lipopolysaccharide. J Biol Chem 5: 16084-16089.
33. Hickman S, Allison EK, Khoury E, (2008) Microglial dysfunction and defective ß-amyloid clearance pathways in aging Alzheimer's disease mice. J Neurosc 13: 8354-8360.
34. McCarty MC, De Vellis J, (1980) Preparation of separate astroglial and oligodendroglial cell cultures from rat cerebral tissues. J Cell Biol 85: 890-902.
35. Bradford MM, (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254.
36. Bethge N, Diel F, Rösick M, Holz J, (1981) Somatostatin half-life: a case report on one healthy volunteer and a three month follow up. Horm Metabl Res 13: 709-710.
37. Feindt J, Becker I, Blömer U, Hugo HH, Mehdorn HM, et al. (1995) Expression of somatostatin receptor subtypes in cultured astrocytes and gliomas. J Neurochem 5: 1997-2005.
38. Zhao L, Teter B, Morihara T, Lim GP, Ambegaokar SS, (2004) Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention. J Neurosci 8: 11120-11126.
39. Walker D, Link J, Lue L, Dalsing-Hernandez JE, Boyes BE, (2006) Gene expression changes by amyloid beta peptide-stimulated human postmortem brain microglia identify activation of multiple inflammatory processes. J Leukoc Biol 3: 596-610.
40. Mouradian MM, Blin J, Giuffra M, Heuser IJ, Baronti F, et al. (1991) Somatostatin replacement therapy for Alzheimer dementia. Ann Neurol 30: 610-613.
41. Lamberts SW, Van Der Lely AJ, de Herder WW, Hofland LJ, (1996) Octreotide. New Engl J Med 334: 246-254.
42. Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, et al. (1982) SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. Life Sci 31: 1133-1140.
43. Shie FS, Woltjer RL, (2007) Manipulation of microglial activation as a therapeutic strategy in Alzheimer's disease. Curr Med Chem 14: 2865-2871.